Effect of membrane flux and dialyzer biocompatibility on survival in end-stage diabetic nephropathy

Nephron - Clinical Practice

Volumn 109, Issue 3, 2008, Pages

  Götz, Angela K ^a   Böger, Carsten A ^a   Popal, Massoud ^a   Banas, Bernhard ^a   Krämer, Bernhard K ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Diabetic nephropathy; Dialysis membrane; Dialyzer biocompatibility; Membrane flux; Survival, end stage diabetic nephropathy

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THROMBOCYTE SLOWING FACTOR;

AGED; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; CAUSE OF DEATH; DIABETIC NEPHROPATHY; FEMALE; GERMANY; HAZARD RATIO; HEART PROTECTION; HEMODIALYSIS; HUMAN; INFECTION; KAPLAN MEIER METHOD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEMBRANE PERMEABILITY; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL;

AGED; BIOCOMPATIBLE MATERIALS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 47949097812     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000145459     Document Type: Article

References (25)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232.
2. Collins AJ, Kasiske B, Herzog C, et al: Excerpts from the United States Renal Data System 2004 annual data report: ATLAS of the end-stage renal disease in the United States. Am J Kidney Dis 2005;45(suppl 1):A5-A7, S1-S200.
3. Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int 2001;60:2041-2055.
4. Ritz E, Rychlik I, Locatelli F, Halimi S: Endstage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
5. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
6. Miskulin DC, Meyer KB, Athienites NV, Martin AA, Terrin N, Marsh JV, Fink NE, Coresh J, Powe NR, Klag MJ, Levey AS: Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. Am J Kidney Dis 2002;39:324-336.
7. Gentil MA, Carriazo A, Pavon MI, Rosado M, Castillo D, Ramos B, Algarra GR, Tejuca F, Banasco VP, Milan JA: Comparison of survival in continuous ambulatory peritoneal dialysis and hospital haemodialysis: a multicentric study. Nephrol Dial Transplant 1991;6:444-451.
8. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996;50:1293-1302.
9. Chauveau P, Nguyen H, Combe C, Chene G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M; French Study Group for Nutrition in Dialysis: Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005;45:565-571.
10. Krane V, Krieter DH, Olschewski M, Marz W, Mann JF, Ritz E, Wanner C: Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007;49:267-275.
11. Böger CA, Götz AK, Krüger B, Hosl M, Schmitz G, Riegger GA, Krämer BK: Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Eur J Med Res 2005;10:161-168.
12. Götz AK, Böger CA, Hirschmann C, Schmitz G, Riegger GAJ, Krämer BK: Effect of HMGCoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. Eur J Med Res 2005;10:155-160.
13. Hoenich NA, Katopodis KP: Clinical characterization of a new polymeric membrane for use in renal replacement therapy. Biomaterials 2002;23:3853-3858.
14. Girndt M, Heisel O, Köhler H: Influence of dialysis with polyamide vs hemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant 1999;14:676-682.
15. Canivet E, Lavaud S, Wong T, Guenounou M, Willemin JC, Potron G, Chanard J: Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994;23:41-46.
16. Dupont WD, Plummer WD Jr: PS power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116-128.
17. Combe C, Chauveau P, Laville M, Fouque D, Azar R, Cano N, Canaud B, Roth H, Leverve X, Aparicio M; French Study Group Nutrition in Dialysis: Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. Am J Kidney Dis 2001;37(1 suppl 2):81-88.
18. Desmeules S, Levesque R, Jaussent I, Leray-Moragues H, Chalabi L, Canaud B: Creatinine index and lean body mass are excellent predictors of long-term survival in haemodiafiltration patients. Nephrol Dial Transplant 2004;19:1182-1189.
19. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-1101.
20. Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992;3:1227-1237.
21. Rocco MV, Cheung AK, Greene T, Eknoyan G; Haemodialysis (HEMO) Study Group: The HEMO Study: applicability and generalizability. Nephrol Dial Transplant 2005;20:278-284.
22. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux haemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263.
23. Böger CA, Götz A, Stubanus M, Banas B, Deinzer M, Krüger B, Holmer SR, Schmitz G, Riegger GAJ, Krämer BK: C-reactive protein as predictor of death in end-stage diabetic nephropathy: role of peripheral arterial disease. Kidney Int 2005;68:217-227.
24. Vanholder R, Ringoir S, Dhondt A, Hakim R: Phagocytosis in uremic and haemodialysis patients: a prospective and cross sectional study. Kidney Int 1991;39:320-327.
25. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.